Question: The beta blocker used for treating mild to severe congestive heart failure is an is an adrenergic antagonist sold under what brand name?

Context articles: Tolvaptan
Congestive hepatopathy
Heart failure with preserved ejection fraction
Denopamine
Beta-3 adrenergic antagonist
Robert R. Ruffolo, Jr
Carvedilol
Beta-2 adrenergic antagonist
Terry's nails
Cardiac asthma

Tolvaptan (INN, trade names Samsca and Jinarc) is a selective, competitive vasopressin receptor 2 antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH).
 Tolvaptan was approved by the U.S. Food and Drug Administration (FDA) on May 19, 2009, and is sold by Otsuka Pharmaceutical Co. under the trade name Samsca and in India is manufactured & sold by MSN laboratories Ltd. under the trade name Tolsama & Tolvat and by Lupin under the brand name Resodim.
Congestive hepatopathy, also known as nutmeg liver and chronic passive congestion of the liver, is liver dysfunction due to venous congestion, usually due to congestive heart failure.
 The gross pathological appearance of a liver affected by chronic passive congestion is "speckled" like a grated nutmeg kernel; the dark spots represent the dilated and congested hepatic venules and small hepatic veins.
 The paler areas are unaffected surrounding liver tissue.
 When severe and longstanding, hepatic congestion can lead to fibrosis; if congestion is due to right heart failure, it is called cardiac cirrhosis.
Heart failure with preserved ejection fraction (HFpEF) is a form of congestive heart failure wherein the amount of blood pumped from the heart's left ventricle with each beat (ejection fraction) is greater than 50%.
 Approximately half of people with heart failure have HFpEF, while the remainder display a reduction in ejection fraction, or heart failure with reduced ejection fraction (HFrEF).
Denopamine (INN) is a cardiotonic drug which acts as a β adrenergic receptor agonist.
 It is used in the treatment of angina and may also have potential uses in the treatment of congestive heart failure and for clearing pulmonary oedema.
 It is marketed in Japan under the brand name Kalgut (カルグート) and available as tablets of 5 and 10 mg, and 5% fine granules.
A Beta-3 adrenergic antagonist (β-adrenoceptor antagonist) is an adrenergic antagonist which blocks the Beta-3 adrenergic receptors of cells, with either high specificity (an antagonist which is selective for β adrenoceptors) like L-748,328, L-748,337 and SR 59,230A or non-specifically (an antagonist for β and for β or β adrenoceptors) like the non-selective betablocker Carvedilol.
Robert R. Ruffolo (born April, 1950, in Yonkers, N.Y.) was president of research and development for Wyeth Pharmaceuticals, and corporate Senior Vice President of Wyeth from 2001 to 2008.
 During his career in the pharmaceutical industry, Ruffolo played a significant role in the discovery and/or development of a number of marketed products, including dobutamine (Dobutrex) for the acute management of congestive heart failure, and eprosartan (Teveten) for hypertension.
 He holds the patent for the discovery of use of carvedilol (Coreg) for the treatment of congestive heart failure, and he led the research team that discovered ropinerole (Requip) for Parkinson's Disease.
Carvedilol, sold under the brand name Coreg among others, is a beta blocker used for treating mild to severe congestive heart failure (CHF), left ventricular dysfunction (LVD) following heart attack in people who are otherwise stable, and for treating high blood pressure.
A Beta-2 adrenergic antagonist (β-adrenoceptor antagonist) is an adrenergic antagonist which blocks the beta-2 adrenergic receptors of cells, with either high specificity (an antagonist which is selective for β adrenoceptors) like Butaxamine and ICI-118,551, or non-specifically (an antagonist for β and for β or β adrenoceptors) like the non-selective betablocker Propranolol.
Terry's nails is a physical condition in which a person's fingernails or toenails appear white with a characteristic "ground glass" appearance without any lunula.
 The condition is thought to be due to a decrease in vascularity and an increase in connective tissue within the nail bed.
 It frequently occurs in the setting of liver failure, cirrhosis, diabetes mellitus, congestive heart failure, hyperthyroidism, or malnutrition.
 Eighty percent of patients with severe liver disease have Terry's nails, but they are also found in patients with kidney failure, in patients with congestive heart failure and are described as a brown arc near the ends of the nails.
 The recognition of characteristic nail patterns, such as Terry’s nails, may be a helpful herald for early diagnosis of systemic diseases.
Cardiac asthma is a medical diagnosis of wheezing, coughing or shortness of breath due to congestive heart failure.
 It is known as cardiac asthma because the symptoms mimic ordinary asthma (bronchial asthma).
 One study found that patients with cardiac asthma represented one third of congestive heart failure in elderly patients.